Crossref
Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?
Clinical Diabetology · 2024
DOI: 10.5603/cd.101353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Diabetology, 2024. Verfasst von Magdalena Walicka und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Walicka, M., & Franek, E. (2024). Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. https://doi.org/10.5603/cd.101353
Vancouver
Walicka M, Franek E. Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?. Clinical Diabetology. 2024. doi:10.5603/cd.101353
BibTeX
@article{Walicka2024,
author = {Walicka, Magdalena and Franek, Edward},
title = {Will Continuous Glucose Monitoring Metrics Replace Hemoglobin A1c in Assessing the Risk of Retinopathy (and Other Complications) in Patients with Type 2 Diabetes?},
journal = {Clinical Diabetology},
year = {2024},
doi = {10.5603/cd.101353}
}
EUVIMED